secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aktis Oncology, Inc. (AKTS)
CIK:        0002035832
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010354
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aktis Oncology adopts classified board, supermajority vote, and eliminates written consent post-IPO
--------------------------------------------------------------------------------

- Filed amended charter authorizing 480M shares of common, 10M Class A common, and 10M undesignated preferred stock.
- Adopted classified board with staggered three-year terms; removal of directors requires two-thirds vote for cause.
- Eliminated stockholder action by written consent in lieu of meetings.
- Amended bylaws to establish procedures for stockholder proposals and director nominations.
- All changes effective Jan 12, 2026 in connection with IPO completion, as previously disclosed in S-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/0001193125-26-010354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2035832/000119312526010354/d932945d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer